Dupilumab as a novel therapy to treat adrenergic urticaria

Abstract

Adrenergic urticaria (AU) is a rare and infrequently reported disease that presents with intermittent outbreaks of stress-induced diffuse pruritic urticarial papules. First described in 1985,1 there has been growing literature further elucidating the mechanism of the disease and novel therapeutic options. A frequently occurring challenge in the diagnosis of AU is differentiating it from the more common cholinergic urticaria (CU). In AU, the papules are surrounded by halos of hypopigmented and vasoconstricted skin, whereas in CU, the small papules are surrounded by large red flares.